Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2004;21(4):297-304.
doi: 10.1385/MO:21:4:297.

Monoclonal antibodies in the treatment of chronic lymphocytic leukemia

Affiliations
Review

Monoclonal antibodies in the treatment of chronic lymphocytic leukemia

Nina Shih Liu et al. Med Oncol. 2004.

Abstract

Traditional therapy for chronic lymphocytic leukemia (CLL) has consisted of alkylating agents, purine analogs, or a combination of these drugs. These agents are effective at producing remissions but are not curative.Thus, new drugs are still needed to improve the outcome of patients with CLL. The introduction of monoclonal antibodies, such as rituximab and alemtuzumab, provides a novel therapeutic modality.Rituximab is an active agent in CLL. Standard doses of rituximab result in higher response rates in previously untreated than in relapsed patients but low complete response (CR) rates. Rituximab is most effective in combination with chemotherapy, especially fludarabine-based regimens in the first-line and salvage setting. Rituximab is also useful in the treatment of complications of CLL, such as pure red cell aplasia, autoimmune thrombocytopenia, and autoimmune hemolytic anemia. Alemtuzumab has impressive activity in patients with refractory CLL and may play an important role in the consolidation treatment of CLL. Alemtuzumab is most efficacious at clearing disease in the peripheral blood and bone marrow. Bulky lymphadenopathy is less sensitive to therapy. Because of the significant lymphopenia associated with alemtuzumab, antibacterial and antiviral prophylaxis should always be used.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Blood. 2002 Mar 15;99(6):2245-7 - PubMed
    1. Br J Haematol. 1997 Jun;97(3):669-72 - PubMed
    1. J Clin Oncol. 2001 Apr 15;19(8):2153-64 - PubMed
    1. Blood. 2001 Sep 15;98(6):1721-6 - PubMed
    1. Br J Haematol. 1996 Apr;93(1):151-3 - PubMed

MeSH terms

LinkOut - more resources